OptiBiotix Health Share News (OPTI)

(Sharecast News) - OptiBiotix Health announced on Thursday that it has received a licence from the Food Standards and Safety Authority India (FSSAI) for its weight management product 'SlimBiome' to be manufactured in the country.The AIM-traded firm said the approval was gained by its manufacturing partner Zeon Life Sciences for both SlimBiome itself, and SlimBiome-containing products.It said FSSAI licence approval involved both ingredient and quality verification to ensure the product and manufacturing process was of a high standard, and was an essential regulatory requirement to manufacture and distribute food products in India.The licence approval would allow Zeon to fulfil orders arising from OptiBiotix's recent visit to India for SlimBiome and SlimBiome-containing products in its own manufacturing site. Its board described it as a "strategic step" to add manufacturing in Asia to the supply chain, and extend the market opportunity for its patented weight management product into the Indian market with an established partner.Zeon boasted a number of large Indian and international healthcare companies such as Danone, GNC, Decathlon, Sun Pharma and Herbalife among its customers, and was awarded 'Nutraceutical Manufacturing Company of the Year' in 2017 by the Associated Chambers of Commerce and Industry of India."We are really pleased that Zeon has received FSSAI approval to manufacture SlimBiome in India," said OptiBiotix chief executive officer Stephen O'Hara."This allows them to fulfil partner orders and meet the needs of other partners interested in selling SlimBiome and SlimBiome-containing products in India."We have been really impressed with the professionalism of Zeon and the speed at which they are creating interest and orders for our products in India."O'Hara said achieving FSSAI approval rapidly was a significant achievement, describing it as an important step in completing the supply chain to meet the needs of existing and new corporate partners in India and southern Asia."This agreement is another step in a strategy designed to build multiple revenue streams from ingredient sales, and white label and own label branded consumer and pharmaceutical products across multiple channels with industry partners from around the world."